Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; and (xiii) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31
'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... PureTech , a science and technology R&D company focused  ... in the healthcare sector, announced today the appointment of ... the Board of Directors of Sanofi, to its Board ... pleasure to know Chris for many years and I ... more closely now," said Dr. Robert Langer , ...
(Date:2/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... that develops and commercializes proprietary technologies and products for ... results for the fiscal first quarter ended December  31, ... Canadian dollars (CAD), unless otherwise stated. ... business from our existing customers and add to our ...
(Date:2/26/2015)... 2015 DuPont Executive Vice President James ... research advancements and product launches across the Agriculture and ... Merrill Lynch 2015 Global Agriculture Conference. ... supplies the last two years, long-term demand for agricultural ... the last decade, when demand for corn and soybeans ...
(Date:2/26/2015)... -- The healthcare landscape is rapidly and radically changing. To ... host its 20 th Anniversary Medical Technologies 2015: ... 10, at the Hilton San Diego Resort and Spa in ... event is a platform for global medical devices, diagnostics, life ... how to succeed in an uncertain future. Participants ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... , PURCHASE, N.Y., Oct. 15 Nutrition 21, Inc. ... nutritional supplements under the Iceland Health®, Chromax® and Diabetes ... improve cardiovascular health, enhance memory and reduce chronic joint ... and the full fiscal year ended June 30, 2009. ...
... MedImmune today announced that researchers will present data on ... the American College of Rheumatology, from October 17 to ... Pennsylvania. , "Through our research into novel disease ... our mission of using scientific excellence to deliver life-changing ...
... Today, Formatech, Inc. announced that GeoVax Labs, Inc.,s ... the first clinical candidate that is formulated and filled under ... be completed in January 2010. Under this program, Formatech ... one lot of the vaccine for use in support of ...
Cached Biology Technology:Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 2Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 3Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 4Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 5Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 6MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 2Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 4
(Date:2/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ... "Global 2D Gesture Recognition Market 2015-2019" report ... forecast the Global 2D Gesture Recognition market to ... period 2014-2019 The increased demand for ... of the major trends in the market. The ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... The 12th International Coral Reef Symosium will bring ... communicate their science and hear their latest advances ... Their research and findings are fundamental in informing ... conservation and sustainable use of coral reefs. ...
... 2012, London, United Kingdom, and Shenzhen, China ... Sequencing in Cancer", co-organized by BGI, the world,s ... successfully conducted in London, UK. Around 70 experts, ... and biotechnology industries attended the meeting with the ...
... hindered data collection on ESA,s SMOS water mission have been ... Aquarius mission, which measures ocean salinity at the same frequency. ... cell phone too close to a speaker: seconds before the ... is radio interference an unwanted reception of radio signals. ...
Cached Biology News:12th International Coral Reef Symposium 2The genomics symposium to boost the further development of cancer research 2SMOS satellite measurements improve as ground radars switch off 2
... colony stimulating factors for assays of mouse ... and fetal liver. Suitable for the ... CFU-GEMM when added to methylcellulose at a ... erythropoietin. Will also support growth of ...
...
Piperazine-N',N'-bis(2-ethanesulfonic acid), monosodium salt...
... constitute the principal excitatory neurotransmitter ... of glutamate receptors exist: Ionotropic ... glutamate receptors are oligomeric complexes ... KAI-2) which comprise ligand-gated calcium ...
Biology Products: